NSE:AUROPHARMA2! The stock has broken down and retested, therefore may undergo a correction in the short term. Trade is supported by Resistances Nearby. Risk Reward Ratio - 2:1 SL is placed above the resistance zone & the lower trendline.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
were up 15% AH and trying to consolidate if we can hold the $0.49 area and stay out of oversold stoch on the daily beating $0.545 and breaking $0.668 level stock should revisit the $0.71-$0.78 area predicting rangebound price action
The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren;...
The lows of this bottom are rising. That is a sign of larger lots on the buy side and weaker smaller lots selling on the bounce. Profit-taking has occurred after the gap up to resistance as Dark Pools pause their accumulation. Price is now outside of their buy zone.
www.tradingview.com FSD Pharma has been ahead of the bearish behaviors we are beginning to see in heavily weighted areas of the market. On top of that, the entire cannabis sector of the market has been experiencing this type of behavior quite some time way before these big sell offs in fear of inflation rates and interest. Now keep in mind once these sell offs...
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19. And the Market Cap is only...
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
A very nice ascending triangle pattern forming, indicating continuation long. Moving averages trending bullish after 2 years of consolidation. RSI attempting to push through resistance. Ideally look to add on weakness however if breakout occurs we should be seeing some nice upside. DYOR NFA. Take care everybody.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
novavax blew up after announcing it was making a covid vaccine. they eventually parléd this into a montly uptrend that lasted until september '21. since then it has seen a major decline. the stock is attempting to end that now, or at least find a temporary rally from new multi year lows. this could lead to a short squeeze zipping the price back up towards weekly...
AMBU is very low right now and it seems like it could go very high with the OMX C25 Index . It is at the lowest for almost 2 years and with the interest rates going down it could lift the shares a lot. There is a very strong support level under it and a good resistance goal.
Took a little nibble on NVNO. Chat doesnt look to bad with price at the bottom of the range and making a nice W. The book also look pretty clean with a low share count finviz.com
At the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was...
DIVISLAB have taken support and forming pole and flag . Going to break channel and start up move. Targets are mentioned, must comment if have any suggestion. NSE:DIVISLAB
GDRX heading to <$20. From there should start reversal. Based on quarterly result may do some consolidation. Would take ~6-9 months to reclaim $40. If interested look out for an entry around ~$18.
Buying Moderna here, may be printing a double bottom on weekly. They arent going to let this pandemic go away so banking on more vaccines and more fun for a few more years at least. It is still WAY up from a few years ago so setting tight stops. Not advise.